|
0
|
|
Immunotherapy for invasive Candida infections: Translating host-directed strategies into clinical practice.
(linkinghub.elsevier.com)
|
Sprute R
…
Ibrahim AS
Clinical Microbiology and Infection
2026-09-07
|
#immunotherapy
#candidiasis
#fungal
#innate immunity
#cytokine
|
|
0
|
|
A microbial chromatin remodeler drives gastric cancer progression and immune evasion by reprogramming the host epigenome.
(linkinghub.elsevier.com)
|
Xie X
…
Lee MH
Cell Host & Microbe
2026-09-07
|
#gastric cancer
#microbiome
#immunotherapy
#epigenetics
#checkpoint-blockade
|
|
0
|
|
Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial.
(nature.com)
|
Shaverdian N
…
Chaft JE
Nature Communications
2026-09-07
|
#clinical trial
#immunotherapy
#lung cancer
#chemoradiation
#immunity
|
|
0
|
|
Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion.
(nature.com)
|
Zeng Q
…
Huang X
Nature Communications
2026-09-07
|
#car-t
#immunotherapy
#activation
#transcriptomics
|
|
0
|
|
Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis.
(nature.com)
|
Kong W
…
Zhang J
Nature Communications
2026-09-07
|
#immunotherapy
#oncology
#biomarker
#carcinoma
#metabolism
|
|
0
|
|
PPM1L-dependent PD-L1 dephosphorylation orchestrates tumor-type-specific ubiquitin ligase recognition to govern its degradation.
(linkinghub.elsevier.com)
|
Li P
…
Ren H
Cell Reports
2026-09-07
|
#immunotherapy
#ubiquitination
#cancer
#protein degradation
#pd-l1
|
|
0
|
|
Dendritic cell centric nanoengineering couples antigen acquisition and STING activation for cancer immunotherapy.
(linkinghub.elsevier.com)
|
Xiang S
…
Wang J
Cell Reports Medicine
2026-09-07
|
#cancer
#immunotherapy
#dendritic cell
#nanoparticles
#sting
|